Literature DB >> 11400194

High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood.

N Brignol1, L M McMahon, S Luo, F L Tse.   

Abstract

A semi-automated high-throughput liquid/liquid extraction (LLE) assay was developed for RAD001 and cyclosporin A (CsA) in human blood. After addition of internal standard and ammonium hydroxide, samples were extracted twice with methyl tert-butyl ether (MTBE). The organic extract was evaporated to dryness and reconstituted in mobile phase. Where possible, sample transfer and LLE steps were automated using a Tomtec Quadra 96 workstation. Samples were analyzed using ESI-LC/MS/MS employing the transitions of ([M + NH(4)](+) --> [M + H](+)) for CsA and ([M + NH(4)](+) --> [M + H-(CH(3)OH + H(2)O)](+)) for RAD001, under isocratic chromatographic conditions (75:25, (v/v), acetonitrile/20 mM ammonium acetate) with a run time of 3.6 min. A lower limit of quantitation (LLOQ) of 0.368 ng/mL and 5.23 ng/mL was achieved for RAD001 and CsA, respectively, using a sample volume of 0.3 mL for the analysis. The method was validated over a 3-day period and the resulting calibration curves had a correlation coefficient >0.99 over the concentration range 0.368 to 409 ng/mL and 5.24 to 1748 ng/mL for RAD001 and CsA, respectively. The inter-day coefficient of variation (CV) was less than 15% at the LLOQ for both compounds. The method was applied to the analysis of clinical samples. Under normal working conditions four 96-well plates could be extracted and LC/MS analysis completed in less than 28 h. A marked improvement in sample throughput efficiency was realized with this LLE method when compared to existing solid phase extraction (SPE) methods which deal with both RAD001 and CsA. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11400194     DOI: 10.1002/rcm.323

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  8 in total

1.  A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).

Authors:  Karen E Bullock; William P Petros; Islam Younis; Hope E Uronis; Michael A Morse; Gerard C Blobe; S Yousuf Zafar; Jon P Gockerman; Joanne J Lager; Roxanne Truax; Kellen L Meadows; Leigh A Howard; Margot M O'Neill; Gloria Broadwater; Herbert I Hurwitz; Johanna C Bendell
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-16       Impact factor: 3.333

2.  Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.

Authors:  J M Kovarik; D Beyer; M N Bizot; Q Jiang; M J Allison; R L Schmouder
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

3.  Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

Authors:  Suresh S Ramalingam; R Donald Harvey; Nabil Saba; Taofeek K Owonikoko; John Kauh; Dong M Shin; Shi-Yong Sun; Sandra Strychor; Mourad Tighiouart; Merrill J Egorin; Haian Fu; Fadlo R Khuri
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

4.  Effect of multiple-dose erythromycin on everolimus pharmacokinetics.

Authors:  J M Kovarik; D Beyer; M N Bizot; Q Jiang; M Shenouda; R L Schmouder
Journal:  Eur J Clin Pharmacol       Date:  2005-01-27       Impact factor: 2.953

5.  Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat.

Authors:  S L Able; R L Fish; H Bye; L Booth; Y R Logan; C Nathaniel; P Hayter; S D Katugampola
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

6.  Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Ana M Molina; Darren R Feldman; Martin H Voss; Michelle S Ginsberg; Michael S Baum; Dion R Brocks; Patricia M Fischer; Michael J Trinos; Sujata Patil; Robert J Motzer
Journal:  Cancer       Date:  2011-09-06       Impact factor: 6.860

7.  A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.

Authors:  Taofeek K Owonikoko; Suresh S Ramalingam; Daniel L Miller; Seth D Force; Gabriel L Sica; Jennifer Mendel; Zhengjia Chen; Andre Rogatko; Mourad Tighiouart; R Donald Harvey; Sungjin Kim; Nabil F Saba; Allan Pickens; Madhusmita Behera; Robert W Fu; Michael R Rossi; William F Auffermann; William E Torres; Rabih Bechara; Xingming Deng; Shi-Yong Sun; Haian Fu; Anthony A Gal; Fadlo R Khuri
Journal:  Clin Cancer Res       Date:  2015-02-11       Impact factor: 12.531

Review 8.  Clinical pharmacokinetics of everolimus.

Authors:  Gabriele I Kirchner; Ivo Meier-Wiedenbach; Michael P Manns
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.